Zev Wainberg, Md, Regarding Bemarituzumab As A Single Agent In The Treatment Of Gastric Cancer

Zev Wainberg, MD, regarding bemarituzumab as a single agent in the treatment of gastric cancer

Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer

FIGHT: bemarituzumab + mFOLFOX6 in first-line advanced gastric cancer

Zev Wainberg, MD, discusses the safety profile of bemarituzumab

Bemarituzumab + Chemotherapy Improve Outcome in Advance Gastric and Gastroesophageal Junction Cancer

Zev Wainberg, MD, explains appropriate therapy following initial treatment for GI & GE tumors

Metastatic Gastric Cancer: Novel Agents Targeting FGF

Next steps in gastric cancer

Standard-of-Care, Second-Line, and Future Therapies for GEJ and Esophageal Adenocarcinoma

Dr. Wainberg discusses Advances in Chemotherapy for Pancreatic Cancer

HirshbergFoundation

Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy

PeerView Oncology

Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021

Breaking Down Bemarituzumab for Gastric, GEJ Cancer: Insights From the FIGHT Trial

GI Oncology Now

Zev Wainberg, MD, on checkpoint inhibition with chemotherapy in pancreatic cancer

NALIRIFOX as frontline therapy for PDAC

Bemarituzumab + mFOLFOX6 in first-line advanced gastric/gastroesophageal junction adenocarcinoma

Bemarituzumab in solid tumors

Genomic landscape of late-stage gastric cancer treated with pembrolizumab

Other Immunotherapy Approaches in Gastric/GEJ Cancers

12 Things NO ONE Tells You About CHEMO (DON’T MISS THIS)

Dr. Amy - Cancer Expert & Cancer Survivor